Adalimumab induced-inflammatory myopathy in rheumatoid arthritis;Miopatia inflamatória induzida por adalimumab na artrite reumatóide

Acta Reumatologica Portuguesa

Volumn 37, Issue 2, 2012, Pages 180-184

  de Souza, Fernando Henrique Carlos ^a   Barros, Thiago Bitar Morais ^a   Levy Neto, Mauricio ^a   Shinjo, Samuel Katsuyuki ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adalimumab; Antisintetase syndrome; Dermatomyositis; Immunobiologics; Polymyositis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MYOSITIS; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MYOSITIS;

EID: 84870039568     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008; 22: 847-861.
2. Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010; 29: 563-566.
3. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006; 55: 982-984.
4. Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol 2006; 16: 410-411.
5. Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy-three examples. J Rheumatol 2008; 35: 2074-2076.
6. Musiał J, Undas A, Celi ska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 1566-1568.
7. Ishiguro T, Takayanagi N, Miyahara Y, Yanagisawa T, Sugita Y. Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi 2010; 48: 240-246.
8. Ishikawa Y, Yukawa N, Kawabata D, et al. A case of antisyn -thetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol 2011; 30: 429-332.
9. Brunasso AMG, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010; 37: 1549.
10. Hikarata M. Humoral aspects of polymiositis/dermatomyositis. Mod Rheumatol 2000; 10: 199-206.
11. Kalluri M, Sahn S, Oddis C. Clinical profile of PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135: 1550-1556.
12. Nishikai M, Reichlin M. Heterogeneity of precipita ting antibodies in polymyositis and dermatomyositis. Characterization of the anti Jo-1 antibody system. Arthitis Rheum 1980; 23: 881-888.
13. Bunn CC, Bernstein RM, Mathews MB. Autoantibo dies against alanyl-tRNA synthetase and tRNA Ala coexist and are associated with myositis. J Exp Med 1986; 163: 1281-1291.
14. Mathews MB, Reichlin M, Hughes GR, Bernstein RM. Antithreonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984; 160: 420-434.
15. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990; 144: 1737-1743.
16. Hirakata M, Suwa A, Nagai S, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162: 2315-2230.